Financial reports
ARS
2023 FY
Annual report to shareholders
14 Mar 24
10-K
2023 FY
Annual report
22 Feb 24
10-Q
2023 Q3
Quarterly report
8 Nov 23
10-Q
2023 Q2
Quarterly report
9 Aug 23
10-Q
2023 Q1
Quarterly report
10 May 23
ARS
2022 FY
Annual report to shareholders
16 Mar 23
10-K
2022 FY
Annual report
23 Feb 23
10-Q
2022 Q3
Quarterly report
9 Nov 22
10-Q
2022 Q2
Quarterly report
10 Aug 22
10-Q
2022 Q1
Quarterly report
11 May 22
Current reports
8-K
Pfizer Reports First-Quarter 2024 Results
1 May 24
8-K
Submission of Matters to a Vote of Security Holders
29 Apr 24
8-K
Pfizer Reports Full-Year 2023 Results and Reaffirms Full-Year 2024 Financial Guidance
30 Jan 24
8-K
Pfizer Recommends Shareholders Reject the Below-Market Mini-Tender Offer by TRC Capital Investment Corporation
10 Jan 24
8-K/A
Pfizer Completes Acquisition of Seagen
14 Dec 23
8-K
Pfizer Completes Acquisition of Seagen
14 Dec 23
8-K
Full-Year 2024 Revenue Guidance(1) Range of $58.5 to $61.5 Billion Includes Expected Contribution from Seagen Acquisition
13 Dec 23
8-K
Pfizer Receives All Required Regulatory Approvals to Complete the Acquisition of Seagen
12 Dec 23
8-K
Pfizer Reports Third-Quarter 2023 Results
31 Oct 23
8-K
Pfizer Amends U.S. Government Paxlovid Supply Agreement and Updates Full-Year 2023 Guidance
13 Oct 23
Registration and prospectus
S-3ASR
Automatic shelf registration
23 Feb 24
S-8
Registration of securities for employees
23 Feb 24
424B5
Prospectus supplement for primary offering
18 May 23
FWP
Free writing prospectus
16 May 23
424B3
Prospectus supplement
15 May 23
POSASR
Automatic shelf registration (post-effective amendment)
15 May 23
S-8
Registration of securities for employees
24 Feb 23
25-NSE
Exchange delisting
7 Mar 22
424B5
Prospectus supplement for primary offering
17 Aug 21
FWP
Free writing prospectus
16 Aug 21
Proxies
PX14A6G
Letter to shareholders
16 Apr 24
DEFA14A
Additional proxy soliciting materials
11 Apr 24
DEFA14A
Additional proxy soliciting materials
11 Apr 24
DEFA14A
Additional proxy soliciting materials
11 Apr 24
DEFA14A
Additional proxy soliciting materials
9 Apr 24
DEFA14A
Additional proxy soliciting materials
28 Mar 24
DEFA14A
Additional proxy soliciting materials
28 Mar 24
DEFA14A
Additional proxy soliciting materials
14 Mar 24
DEF 14A
Definitive proxy
14 Mar 24
PX14A6G
Letter to shareholders
12 Apr 23
Other
UPLOAD
Letter from SEC
14 Apr 22
CORRESP
Correspondence with SEC
12 Apr 22
CORRESP
Correspondence with SEC
23 Dec 21
UPLOAD
Letter from SEC
10 Dec 21
CT ORDER
Confidential treatment order
15 Mar 19
SD
Conflict minerals disclosure
31 May 18
SD
Conflict minerals disclosure
31 May 17
CERTNYS
Certification of approval for NYSE listing
7 Mar 17
NO ACT
No action letter
10 Feb 17
NO ACT
No action letter
31 Jan 17